Syndax Pharmaceuticals, Inc. (SNDX)
| Market Cap | 917.71M |
| Revenue (ttm) | 139.33M |
| Net Income (ttm) | 15.48M |
| Shares Out | 56.23M |
| EPS (ttm) | 0.27 |
| PE Ratio | 59.56 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 483,163 |
| Open | 15.27 |
| Previous Close | 15.18 |
| Day's Range | 14.70 - 16.35 |
| 52-Week Range | 13.27 - 22.71 |
| Beta | 1.53 |
| Analysts | Buy |
| Price Target | 33.51 (+105.3%) |
| Earnings Date | May 9, 2022 |
About SNDX
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic ...
Financial Performance
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for SNDX stock is "Buy." The 12-month stock price forecast is 33.51, which is an increase of 105.33% from the latest price.
News
Syndax Announces Participation at Two Upcoming Investor Conferences
WALTHAM, Mass. , May 26, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline ...
Syndax Announces Participation at Citi's Biopharma Virtual Co-Panel Day
WALTHAM, Mass. , May 11, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline ...
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Lags Revenue Estimates
Syndax (SNDX) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Syndax Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical and Business Update
– Topline data from revumenib (SNDX-5613) and axatilimab pivotal programs expected starting in 1H23; Company remains on track for two FDA filings in 2023 – – BEAT-AML and AUGMENT-102 trials assessing re...
Syndax to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 9, 2022
WALTHAM, Mass. , May 2, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline o...
Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
WALTHAM, Mass., March 4, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline ...
Syndax Pharmaceuticals Reports Fourth Quarter 2021 Financial Results and Provides Clinical and Business Update
WALTHAM, Mass., March 1, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline ...
Syndax Pharmaceuticals Announces Appointment of Kate Madigan, M.D., as Chief Medical Officer
WALTHAM, Mass., March 1, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline ...
Syndax Announces Participation at Two Upcoming Investor Conferences
WALTHAM, Mass., Feb. 28, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline ...
Syndax Pharmaceuticals Announces Transition of Michael A. Metzger to Chief Executive Officer; Briggs W.
WALTHAM, Mass., Feb. 3, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline o...
Syndax Announces Presentation at B. Riley Securities' 2022 Oncology Conference
WALTHAM, Mass., Jan. 20, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline ...
Syndax Announces Presentation at 40th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 7, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline o...
Syndax Announces Orphan Drug Designation Granted to SNDX-5613 by European Commission for the Treatment of Acute Myelo...
WALTHAM, Mass., Dec. 22, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline ...
Syndax Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional S...
WALTHAM, Mass., Dec. 20, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline ...
Syndax Announces Pricing of $75.3 Million Public Offering
WALTHAM, Mass., Dec. 15, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline ...
Syndax Announces Proposed Public Offering of Common Stock
WALTHAM, Mass., Dec. 15, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline ...
Syndax Pharma Posts Additional Data On Clinical Activity, Responses From Early-Stage Leukemia Trial
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) revealed updated data from the Phase 1 dose-escalation portion of the AUGMENT-101 trial of SNDX-5613 in patients with mutant nucleophosmin (mNPM1) or mixed-line...
Syndax Pharmaceuticals Announces Additional Positive Data Demonstrating Continued Robust Clinical Activity with Durab...
WALTHAM, Mass., Dec. 13, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline ...
Syndax Pharmaceuticals Announces Updated Positive Data Demonstrating Broad Activity and Tolerability of Axatilimab in...
WALTHAM, Mass., Dec. 11, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline ...
Syndax Pharmaceuticals Announces Closing of Global Collaboration and License Agreement for Axatilimab
WALTHAM, Mass., Dec. 9, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) announced today that the Hart-Scott-Rodino (HSR) antitrust waiting period had expired and that the parties closed...
Syndax Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical and Business Update
WALTHAM, Mass., Nov. 15, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline ...
Syndax to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 15, 2021
WALTHAM, Mass., Nov. 8, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline o...
Syndax Pharmaceuticals to Present Updated Data from SNDX-5613 and Axatilimab Clinical Programs During Oral Sessions a...
WALTHAM, Mass., Nov. 4, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announce...
Can Syndax (SNDX) Climb 48% to Reach the Level Wall Street Analysts Expect?
The consensus price target hints at a 47.7% upside potential for Syndax (SNDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate rev...